Evidence behind the WHO guidelines: Hospital care for children

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A combination of ampicillin and gentamicin as first line therapy for suspected non-meningitic septicaemia in children is apprropriate first-line therapy. Ampicilin should be given in high dose (200-300 mg/kg/day) to overcome penicillin-resistance among pneumococci. Once daily gentamicin has been proven to be safe, effective and associated with less toxicity than more frequent doses. Where meningitis is suspected, the options are chloramphenicol of a third-generation cephalosporin. A third-generation cephalosporin (e.g. ceftriaxone) will be preferable to chloramphenicol where resistance to chloramphenicol and penicillin among H. influenzae and S. pneumoniae is common. Anti-staphylococcal antibiotics (such as betalactamase stable penicillins flucloxacillin or cloxacillin) should be given as first-line treatment if there are suggestive skin lesions, abscesses, bone or joint infection, or if other signs of staphylococcal infection (such as pneumatocoeles or empyema) are present. If either flucloxacillin or cloxacillin are not available, chloramphenicol will have some anti-staphylococcal activity. Further studies are needed to follow antimicrobial susceptibility in developing counries so that empirical treatment recommendations maintain a strong evidence base. Restricting the use of third-generation cephalosporins and beta-lactamase stable penicillins to where there are specific indications will reduce the development of antibiotic resistance.

Original languageEnglish (US)
Pages (from-to)46-48
Number of pages3
JournalJournal of Tropical Pediatrics
Volume52
Issue number1
DOIs
StatePublished - Feb 2006

Fingerprint

Child Care
Chloramphenicol
Floxacillin
Penicillins
Guidelines
Cloxacillin
Cephalosporins
Gentamicins
Cephalosporinase
Chloramphenicol Resistance
Penicillin Resistance
Staphylococcal Infections
Empyema
Ceftriaxone
Therapeutics
Ampicillin
Microbial Drug Resistance
Streptococcus pneumoniae
Meningitis
Abscess

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Evidence behind the WHO guidelines : Hospital care for children. / Ryan, Mary; McCracken, George H.

In: Journal of Tropical Pediatrics, Vol. 52, No. 1, 02.2006, p. 46-48.

Research output: Contribution to journalArticle

@article{033d06c56eab4517b7e18dd8c081bd62,
title = "Evidence behind the WHO guidelines: Hospital care for children",
abstract = "A combination of ampicillin and gentamicin as first line therapy for suspected non-meningitic septicaemia in children is apprropriate first-line therapy. Ampicilin should be given in high dose (200-300 mg/kg/day) to overcome penicillin-resistance among pneumococci. Once daily gentamicin has been proven to be safe, effective and associated with less toxicity than more frequent doses. Where meningitis is suspected, the options are chloramphenicol of a third-generation cephalosporin. A third-generation cephalosporin (e.g. ceftriaxone) will be preferable to chloramphenicol where resistance to chloramphenicol and penicillin among H. influenzae and S. pneumoniae is common. Anti-staphylococcal antibiotics (such as betalactamase stable penicillins flucloxacillin or cloxacillin) should be given as first-line treatment if there are suggestive skin lesions, abscesses, bone or joint infection, or if other signs of staphylococcal infection (such as pneumatocoeles or empyema) are present. If either flucloxacillin or cloxacillin are not available, chloramphenicol will have some anti-staphylococcal activity. Further studies are needed to follow antimicrobial susceptibility in developing counries so that empirical treatment recommendations maintain a strong evidence base. Restricting the use of third-generation cephalosporins and beta-lactamase stable penicillins to where there are specific indications will reduce the development of antibiotic resistance.",
author = "Mary Ryan and McCracken, {George H.}",
year = "2006",
month = "2",
doi = "10.1093/tropej/fmk007",
language = "English (US)",
volume = "52",
pages = "46--48",
journal = "Journal of Tropical Pediatrics",
issn = "0142-6338",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Evidence behind the WHO guidelines

T2 - Hospital care for children

AU - Ryan, Mary

AU - McCracken, George H.

PY - 2006/2

Y1 - 2006/2

N2 - A combination of ampicillin and gentamicin as first line therapy for suspected non-meningitic septicaemia in children is apprropriate first-line therapy. Ampicilin should be given in high dose (200-300 mg/kg/day) to overcome penicillin-resistance among pneumococci. Once daily gentamicin has been proven to be safe, effective and associated with less toxicity than more frequent doses. Where meningitis is suspected, the options are chloramphenicol of a third-generation cephalosporin. A third-generation cephalosporin (e.g. ceftriaxone) will be preferable to chloramphenicol where resistance to chloramphenicol and penicillin among H. influenzae and S. pneumoniae is common. Anti-staphylococcal antibiotics (such as betalactamase stable penicillins flucloxacillin or cloxacillin) should be given as first-line treatment if there are suggestive skin lesions, abscesses, bone or joint infection, or if other signs of staphylococcal infection (such as pneumatocoeles or empyema) are present. If either flucloxacillin or cloxacillin are not available, chloramphenicol will have some anti-staphylococcal activity. Further studies are needed to follow antimicrobial susceptibility in developing counries so that empirical treatment recommendations maintain a strong evidence base. Restricting the use of third-generation cephalosporins and beta-lactamase stable penicillins to where there are specific indications will reduce the development of antibiotic resistance.

AB - A combination of ampicillin and gentamicin as first line therapy for suspected non-meningitic septicaemia in children is apprropriate first-line therapy. Ampicilin should be given in high dose (200-300 mg/kg/day) to overcome penicillin-resistance among pneumococci. Once daily gentamicin has been proven to be safe, effective and associated with less toxicity than more frequent doses. Where meningitis is suspected, the options are chloramphenicol of a third-generation cephalosporin. A third-generation cephalosporin (e.g. ceftriaxone) will be preferable to chloramphenicol where resistance to chloramphenicol and penicillin among H. influenzae and S. pneumoniae is common. Anti-staphylococcal antibiotics (such as betalactamase stable penicillins flucloxacillin or cloxacillin) should be given as first-line treatment if there are suggestive skin lesions, abscesses, bone or joint infection, or if other signs of staphylococcal infection (such as pneumatocoeles or empyema) are present. If either flucloxacillin or cloxacillin are not available, chloramphenicol will have some anti-staphylococcal activity. Further studies are needed to follow antimicrobial susceptibility in developing counries so that empirical treatment recommendations maintain a strong evidence base. Restricting the use of third-generation cephalosporins and beta-lactamase stable penicillins to where there are specific indications will reduce the development of antibiotic resistance.

UR - http://www.scopus.com/inward/record.url?scp=31744451877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31744451877&partnerID=8YFLogxK

U2 - 10.1093/tropej/fmk007

DO - 10.1093/tropej/fmk007

M3 - Article

C2 - 16436544

AN - SCOPUS:31744451877

VL - 52

SP - 46

EP - 48

JO - Journal of Tropical Pediatrics

JF - Journal of Tropical Pediatrics

SN - 0142-6338

IS - 1

ER -